Opinion|Videos|July 3, 2024
Current and Emerging Treatment Options and Management of Duchenne Muscular Dystrophy
Author(s)Emma Ciafaloni, MD
An expert on Duchenne muscular dystrophy reviews standard-of-care treatment options and provides clinical insights on adverse effects and safety concerns, particularly with corticosteroids.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Please briefly describe the current standard of care for Duchenne muscular dystrophy (DMD).
- What are the side effects and/or safety concerns associated with long-term use of corticosteroids in patients with DMD?
- Discuss recent approvals and ongoing studies in DMD.
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.
Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.
Christen Kutz, PhD, PA-C, discusses a retrospective survey of neurology providers examining why patients with generalized myasthenia gravis are transitioning to nipocalimab and what real-world outcomes data suggest about its role in the treatment landscape.
At a NeurologyLive Clinical Forum in Philadelphia, Jessica D. Schulte, MD, PhD, of NYU Grossman School of Medicine, discussed how earlier recognition and systemic therapy options are changing the treatment paradigm for patients with NF1-associated plexiform neurofibromas.
Here's some of what is coming soon to NeurologyLive® this week.
PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized myasthenia gravis.
New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later.
A new Bayesian network meta-analysis found nipocalimab's serious adverse event rates compared favorably with other gMG therapies, while overall adverse event rates were comparable.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Solengepras Meets Primary Endpoint in Phase 3 ARISE Trial of Parkinson Disease
2
CSF Biomarkers Identify Shared LRRK2 Pathway Activation in Sporadic and LRRK2-Associated Parkinson Disease
3
Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches
4
Phase 4 THRIVE Data Highlights Eptinezumab’s Impact on Migraine After Prior CGRP Failure
5